Clinical Trial Update: THIO and Cadonilimab in Resectable Hepatocellular Carcinoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating THIO in combination with Cadonilimab for resectable hepatocellular carcinoma. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab
• THIO

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Resectable Hepatocellular Carcinoma | EARLY_Phase 1 | Status: NOT_YET_RECRUITING